Bain Capital Life Sciences Investors’s Hemab Therapeutics COAG Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio COAG Stock Details COAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.6M	Buy	+1,650,000	New	+$45.5M	3.6%	9

Other funds holding COAG

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bain Capital Life Sciences Investors's COAG Position: Q2 2026 in Review

Bain Capital Life Sciences Investors opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 1,650,000 shares worth $60.6M. The stake represents 3.6% of the portfolio and ranks #9 among its holdings.

56 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

Bain Capital Life Sciences Investors held 1,650,000 shares of Hemab Therapeutics worth $60.6M as of Q2 2026.
Hemab Therapeutics was a new Bain Capital Life Sciences Investors position in Q2 2026.
Hemab Therapeutics made up 3.6% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #9 holding.
56 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.